ストックスクリーナーアプリを入手
80.00
3.39%
-2.81
アフターアワーズ：
80.00
Bright Minds Biosciences Inc (DRUG) 最新ニュース
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Precision Trading with Bright Minds Biosciences Inc. (DRUG) Risk Zones - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
DRUG Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bright Minds Biosciences to Present at Upcoming Conferences - Bitget
Biotech Bright Minds targeting drug-resistant epilepsy heads to 3 health events - Stock Titan
Published on: 2026-02-24 23:01:51 - baoquankhu1.vn
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap UpWhat's Next? - MarketBeat
Stock Report: What are Bright Minds Biosciences Incs recent SEC filings showingJuly 2025 Chart Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Baird lowers Bright Minds Biosciences Inc. (DRUG) price target to $126, maintains outperform rating ahead of upcoming trials - MSN
Technical Reactions to DRUG Trends in Macro Strategies - Stock Traders Daily
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials - Finviz
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 7.9%Here's What Happened - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research - MarketBeat
Will Bright Minds Biosciences Inc. benefit from rate cutsWeekly Trading Summary & AI Based Trade Execution Alerts - mfd.ru
7 Most Promising Psychedelic Stocks According to Hedge Funds - Insider Monkey
What are Bright Minds Biosciences Inc.’s recent SEC filings showingRate Cut & Weekly Top Gainers Trade List - mfd.ru
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 6.2%Time to Sell? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Issues Earnings Results, Beats Estimates By $0.28 EPS - MarketBeat
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss - TipRanks
Is Bright Minds Biosciences Inc. stock dividend yield sustainableJuly 2025 Trends & Free Community Supported Trade Ideas - mfd.ru
Will Bright Minds Biosciences Inc. benefit from rising consumer demandQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Trading the Move, Not the Narrative: (DRUG) Edition - Stock Traders Daily
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Bright Minds Biosciences (DRUG) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Rally Mode: Is Bright Minds Biosciences Inc undervalued by DCF analysisJuly 2025 Technicals & AI Powered Market Entry Ideas - baoquankhu1.vn
Dow Update: Will Bright Minds Biosciences Inc. benefit from AI trendsWeekly Profit Recap & High Yield Equity Trading Tips - baoquankhu1.vn
How interest rate cuts could boost Bright Minds Biosciences Inc. stockJuly 2025 Sector Moves & Weekly Setup with ROI Potential - mfd.ru
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 67.5% - MarketBeat
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet - MSN
What are the risks of holding Olin CorporationJuly 2025 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Several Bright Minds Biosciences Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Aug Big Picture: Is SSNC stock trending bullishJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
(DRUG) Volatility Zones as Tactical Triggers - Stock Traders Daily
Price-Driven Insight from (DRUG) for Rule-Based Strategy - Stock Traders Daily
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Nigeria
New epilepsy study tests drug for adults whose seizures resist treatment - Stock Titan
Volume Summary: How Bright Minds Biosciences Inc. stock performs in high volatility markets - Bộ Nội Vụ
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Bright Minds Biosciences Stock Topped the Market on Monday - MSN
Bright Minds Biosciences closes $175 million public offering By Investing.com - Investing.com Nigeria
Warm welcome for Aktis could open up IPO queue: Public Equity Report - BioCentury
Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen - MarketBeat
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline - TipRanks
Bright Minds prices $175M stock offering - MSN
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Bright Minds Biosciences Closes its US$175 Million Public Offering - marketscreener.com
McMillan Advises Bright Minds Bioscience on its USD$175 Million Prospectus Offering - McMillan LLP
Bright Minds Biosciences closes $175 million public offering - Investing.com
Bright Minds Biosciences Closes $175.1 Million Stock Offering - marketscreener.com
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering - manilatimes.net
5.71%
0.02%
大文字化:
|
ボリューム (24 時間):